Editas Medicine, Inc. $50 Million Follow-On Offering

Davis Polk advised the sole book-running manager in connection with the $50 million follow-on offering of 1,970,000 shares of common stock of Editas Medicine, Inc.

The common stock is listed on the NASDAQ Global Select Market under the symbol “EDIT.”

Morgan Stanley acted as sole book-running manager.

Based in Cambridge, Massachusetts, Editas Medicine is a genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. (Picture) and associates Cameron C. Lewis, Jenny J. Choi and Mahfouz Basith. The intellectual property and technology team included counsel David R. Bauer and associates Bonnie Chen and Christopher C. Woller. Counsel Marcie A. Goldstein provided FINRA advice. The tax team included partner Po Sit and associate K. Daniel Berman.

Involved fees earner: Richard Truesdell – Davis Polk & Wardwell; Cameron Lewis – Davis Polk & Wardwell; Jenny Choi – Davis Polk & Wardwell; Mahfouz Basith – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Bonnie Chen – Davis Polk & Wardwell; Christopher Woller – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Po Sit – Davis Polk & Wardwell; K. Daniel Berman – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Morgan Stanley;


Author: Ambrogio Visconti